[
    [
        {
            "time": "2021-03-15",
            "original_text": "Merck Sales Hit Hardest by Pandemic",
            "features": {
                "keywords": [
                    "Merck",
                    "Sales",
                    "Hit",
                    "Pandemic"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Merck Sales Hit Hardest by Pandemic",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-16",
            "original_text": "Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference",
            "features": {
                "keywords": [
                    "Lilly",
                    "Evercore",
                    "ISI",
                    "HealthCONx",
                    "Conference"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Gilead",
                    "Eli Lilly",
                    "Incyte",
                    "Pfizer"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-03-18",
            "original_text": "Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak",
            "features": {
                "keywords": [
                    "Vir Biotech",
                    "CEO",
                    "Covid-19",
                    "Medicine",
                    "Promise",
                    "Outbreak"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Vir Biotechnology CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-19",
            "original_text": "Should Value Investors Choose Eli Lilly and Co (LLY) Stock?",
            "features": {
                "keywords": [
                    "Value Investors",
                    "Eli Lilly",
                    "Stock"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should Value Investors Choose Eli Lilly and Co (LLY) Stock?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-20",
            "original_text": "Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada",
            "features": {
                "keywords": [
                    "Lilly",
                    "Coronavirus",
                    "Treatment",
                    "Interim",
                    "Nod",
                    "Canada"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]